ImmunityBio (IBRX) stock rose over 4% pre-market after securing $75 million in non-dilutive financing from Oberland Capital. Separately, Nant Capital converted $25 million of debt into equity. These moves significantly reduce the company's overall debt and reinforce investor confidence in the biotech firm's balance sheet and stability.